Stock Watch: Investor Reactions Diverge As J&J And Novartis Report Q2 Results

A Good Start To Earnings Season Quickly Reverses

 
• By Andy Smith
  
Generate a summary of this article
Listen to this article
Beta

Both of the first two companies to report second-quarter financials maintained full-year sales guidance. But while Johnson & Johnson’s investors seemed cheered, Novartis’s may have been concerned about familiar issues.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

With the 15% year-to-date gain of the S&P 500 index driven mainly by the largest artificial intelligence and technology companies, it was down to the second-quarter earnings report of another of the index’s bigger constituents – Johnson & Johnson (J&J) – to accelerate or reverse the more recent rotation away from big capitalization stocks, and indicate the life science sector’s financial health. With J&J’s stock price closing up by nearly 4% compared with the NYSE Arca Pharmaceutical Index’s (DRG’s) same-day close modestly into negative territory, the initial signs were good.

[Sidebar#SC150601]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Stock Watch

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.